1. ALLA AKTIER
  2. NYHETER
  3. SCANDINAVIAN REAL HEART

Scandinavian Real Heart

Nyheter Scandinavian Real Heart Nyheter alla bolag

Realheart Receives SEK 6.8 Million Following Directed Share Issue to the European Innovation Council

Västerås, Sweden, July 7, 2025 – Scandinavian Real Heart AB (publ) announces today that the company has received an outstanding payment of approximately SEK 6.8 million from the European Innovation Council (EIC) following the company’s directed share issue communicated on May 2, 2025, wherein it was announced that EIC has subscribed 600,000 shares to the subscription price of SEK 11.31 per share.

The European Innovation Council (EIC) has hitherto subscribed in two separate share issues resolved by the company. Due to the size of the investment and that Realheart acts within a sector of interest to the Swedish state, the transaction has been reviewed according to the Foreign Direct Investment Act, causing a delay in the payment.
 
“This settlement marks the completion of EIC’s participation in yet another financing round for the continued development of our unique technology. In this highly competitive arena, where only one in twenty applying companies receive any form of EIC support, we see this investment as an important external validation of the company’s innovation and potential. We look forward to continuing our constructive dialogue with the agency,” says Ina Laura Perkins, CEO, Realheart.

For more information, please contact:
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21 
E-mail: inalaura.perkins@realheart.se
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se

About Us
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se

Attachments
Realheart Receives SEK 6.8 Million Following Directed Share Issue to the European Innovation Council

Datum 2025-07-07, kl 08:30
Källa MFN
Bifogade filer
Realheart Receives SEK 6.8 Million Following Directed Share Issue to the European Innovation Council
Hej Serverägare! Har du problem med troll och spam? Nu finns möjligheten att sätta en liten avgift, t.ex. 20kr, på discord invites och därmed stoppa många återkommande troll samtidigt som du tjänar lite pengar. Kolla in Invite Paywall.